Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bortezomib
/ administration & dosage
Dexamethasone
/ administration & dosage
Female
Follow-Up Studies
Humans
Lenalidomide
/ administration & dosage
Male
Maximum Tolerated Dose
Middle Aged
Multiple Myeloma
/ drug therapy
Neoplasm Recurrence, Local
/ drug therapy
Panobinostat
/ administration & dosage
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
05 02 2021
05 02 2021
Historique:
received:
21
07
2020
accepted:
23
12
2020
revised:
08
12
2020
entrez:
10
2
2021
pubmed:
11
2
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Additional therapeutic options are needed for relapsed and refractory multiple myeloma (RRMM). We present data from a phase 1b, open-label, dose-escalation study (NCT01965353) of 20 patients with RRMM (median age: 63 years [range: 50-77]) and a median of four prior regimens (range: 2-14); 85% had refractory disease (lenalidomide [80%]; bortezomib [75%]; lenalidomide and bortezomib [50%]). Patients received a median of six cycles (range: 1-74) of panobinostat (10 or 15 mg), lenalidomide 15 mg, bortezomib 1 mg/m
Identifiants
pubmed: 33563894
doi: 10.1038/s41408-021-00407-5
pii: 10.1038/s41408-021-00407-5
pmc: PMC7873303
doi:
Substances chimiques
Bortezomib
69G8BD63PP
Dexamethasone
7S5I7G3JQL
Panobinostat
9647FM7Y3Z
Lenalidomide
F0P408N6V4
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Références
Blood. 2003 May 15;101(10):4055-62
pubmed: 12531799
Blood Cancer J. 2018 Nov 9;8(11):109
pubmed: 30413684
Blood. 2010 Dec 2;116(23):4745-53
pubmed: 20807892
Blood. 2006 Nov 15;108(10):3441-9
pubmed: 16728695
Eur J Haematol. 2017 Sep;99(3):199-206
pubmed: 28504846
Epigenetics. 2014 Nov;9(11):1511-20
pubmed: 25482492
Blood. 2010 Apr 22;115(16):3416-7
pubmed: 20413666
Blood Adv. 2017 Aug 21;1(19):1575-1583
pubmed: 29296798
Lancet. 2017 Feb 4;389(10068):519-527
pubmed: 28017406
Lancet Haematol. 2018 Dec;5(12):e628-e640
pubmed: 30501870
Blood. 2013 Oct 3;122(14):2331-7
pubmed: 23950178
Am J Hematol. 2018 Aug 16;93(8):981-1114
pubmed: 30400719
Leukemia. 2008 Jul;22(7):1419-27
pubmed: 18432260
Clin Cancer Res. 2015 Nov 1;21(21):4767-73
pubmed: 26362997
Haematologica. 2015 May;100(5):670-6
pubmed: 25710456
Lancet Oncol. 2021 Jan;22(1):142-154
pubmed: 33301738
Lancet Haematol. 2016 Nov;3(11):e506-e515
pubmed: 27751707
Clin Epigenetics. 2017 Feb 10;9:17
pubmed: 28203307
J Clin Oncol. 2018 Mar 10;36(8):728-734
pubmed: 29341834
Lancet Oncol. 2014 Oct;15(11):1195-206
pubmed: 25242045
Leukemia. 2018 Feb;32(2):252-262
pubmed: 29257139
Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5
pubmed: 14695887
Blood Rev. 2011 Jul;25(4):181-91
pubmed: 21497966
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
Exp Cell Res. 2018 Feb 15;363(2):196-207
pubmed: 29317217